Daria G. Husni

John Bertagnolli, vice-president of Commercial Operations at Selkirk Pharma, discusses considerations when building and scaling up pharmaceutical facilities, including contamination control and aseptic processing challenges.

The organizations plan to combine etherna’s experience in mRNA and lipid-based nanoparticles with UHasselt’s autoimmune research to treat a variety of auto-immune diseases.

Breyanzi is made from the patient’s own T cells, which are genetically reengineered into CAR-T cells and then delivered through infusion as a one-time treatment.

The new drug delivery site will serve to increase Cresset's reach in the region, answering growing demands from its Asia-Pacific consumers.

The company presented results from its programs for Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy.

One of the first planned areas of focus is the field of preterm birth-associated early onset respiratory disease.

Mariana’s portfolio of radioligand therapies will strengthen Novartis’ radioligand therapy pipeline.

Key areas to invest include manufacturing process improvements, quality management, and AI.

Shanghai Henlius Biotech’s first biosimilar has previously received approvals by the European Commission and National Medical Products Administration.

The collaboration aims to scale-up TreeFrog’s process to produce and amplify cells for Vertex’s type 1 diabetes cell therapies.